COMMUNIQUÉS West-GlobeNewswire
-
FeraMAX is Canada's Top-Ranked Iron Supplement for 11 Consecutive Years
01/04/2026 -
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
01/04/2026 -
Stryker to announce financial results for its first quarter of fiscal year 2026
01/04/2026 -
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
01/04/2026 -
Johns Hopkins Health Plans Sits Down with Dundalk Seniors to Champion Community Connection
01/04/2026 -
Axe Compute Reports $12 Million in Executed Agreements Providing $835 Thousand in Estimated Monthly Income Entering Q2 2026
01/04/2026 -
Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year
01/04/2026 -
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
01/04/2026 -
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
01/04/2026 -
OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI
01/04/2026 -
Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week
01/04/2026 -
Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Virginia based Industrial Manufacturing Client
01/04/2026 -
AAVantgarde appoints Philip Lao as Senior Vice President of Business Development
01/04/2026 -
Soleo Health Selected as an Authorized Specialty Pharmacy of QIVIGY® For Primary Humoral Immunodeficiency (PI) Treatment
01/04/2026 -
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
01/04/2026 -
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
01/04/2026 -
Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026
01/04/2026 -
VivoSim Announces Pricing of up to a $4 Million Public Offering
01/04/2026 -
Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
01/04/2026
Pages